Gilead Sciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GIS.DE | GLAXO.BO | BMY | BIIB | SNY | GSK | |
|---|---|---|---|---|---|---|
| Market cap | 194.11B | 423.63B | 131.21B | 37.61B | 113.74B | 102.53B |
| P/E (TTM) | — | 44.4 | 14.2 | 110.2 | 23.6 | 17.8 |
| Forward P/E | — | 36.9 | 9.6 | 15.6 | 8.9 | 10.3 |
| Price/book | 16.7 | 24.8 | 5.6 | 2.0 | 1.4 | 4.1 |
| Dividend yield | 1.93% | 1.75% | 3.93% | — | 5.10% | 3.55% |
| 1-year change | +45.07% | +6.17% | +37.66% | +62.35% | −4.08% | +8.60% |
| Today | +1.26% | −1.26% | +4.02% | +2.22% | +4.72% | +5.03% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All GIS.DE news ›Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Gilead Sciences increased its quarterly dividend by 3.8% this year. Gilead Sciences (GILD +4.19%) is the leading pharmaceutical company that produces HIV treatments. Its chronic HIV management therapies are largely insulated from…
Gilead Sciences, Inc. $GILD Stock: AIA Group Ltd Reduces Stake
MarketBeat Gilead Sciences, Inc. $GILD Stock: AIA Group Ltd Reduces Stake - AIA Group cut its Gilead stake by 17.9% in the third quarter, selling 7,132 shares and ending the period with 32,632 shares valued at about $4.9 million. Instit
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise - This is the…
Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.
Get Our Latest Research Report on GILD The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share.…
Gilead Sciences, Inc. $GILD Stock Purchased by Provenance Wealth Advisors LLC
GILD stock opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The firm has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The business's 50 day moving…
Gilead Sciences (GILD) Receives a Buy from Morgan Stanley
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. In a report released today, Terence Flynn from Morgan Stanley assigned a Buy rating to Gilead Sciences, with a price target…
Gilead Sciences (GILD) Receives a Rating Update from a Top Analyst
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $175.00. Van…
DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
www.marketscreener.com Published on 11/04/2026 at 05:37 am EST Gilead to Buy Cancer Biotech Tubulis in $5B Deal April 08, 2026 at 04:23 pm EDT
Gilead Sciences Announces Presentation of Late-Breaking Clinical Data and Real-World Evidence At Hiv Glasgow
Gilead Sciences announced its participation in the International Congress on Drug Therapy in HIV Infection , taking place from November 8-11. Results from more than 50 studies, including late-breaking...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com29
- marketbeat.com22
- theglobeandmail.com7
- defenseworld.net6
- seekingalpha.com6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.